{"id":"donepezil-and-lithium","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Polyuria/polydipsia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Donepezil is a cholinesterase inhibitor that prevents the breakdown of acetylcholine, enhancing cognitive function in neurodegenerative conditions. Lithium acts as a mood stabilizer and neuroprotective agent by inhibiting glycogen synthase kinase-3 (GSK-3) and modulating various intracellular signaling cascades. The combination targets both cholinergic deficits and neuroprotective pathways, potentially beneficial in cognitive and mood disorders.","oneSentence":"Donepezil inhibits acetylcholinesterase to increase acetylcholine levels in the brain, while lithium modulates intracellular signaling pathways and neuroprotection.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:35:34.293Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease with mood disturbance or bipolar features"},{"name":"Cognitive impairment with mood instability"}]},"trialDetails":[{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT01191918","phase":"PHASE4","title":"The Efficacy and Safety of AChE Inhibitor Donepezil As Adjunctive Treatment to Mood Stabilizers in Acute Mania","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2005-05","conditions":"Bipolar Disorder, Mania","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aricept"],"phase":"marketed","status":"active","brandName":"Donepezil and Lithium","genericName":"Donepezil and Lithium","companyName":"Shanghai Mental Health Center","companyId":"shanghai-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Donepezil inhibits acetylcholinesterase to increase acetylcholine levels in the brain, while lithium modulates intracellular signaling pathways and neuroprotection. Used for Alzheimer's disease with mood disturbance or bipolar features, Cognitive impairment with mood instability.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}